Navigation Links
Neurochem reports results for third quarter of fiscal 2007
Date:11/7/2007

ment in Innodia Holding to a nominal value. Innodia Inc. is a private, development-stage company engaged in developing novel drugs for the treatment of type 2 diabetes and underlying diseases.

Liquidity and Capital Resources

As at September 30, 2007, the Company had available cash, cash equivalents and marketable securities of $70,637,000, compared to $48,758,000 at December 31, 2006. The increase is primarily due to proceeds received from the issue of convertible notes in May 2007 and is partially offset by funds used in operating activities.

On May 2, 2007, the Company issued $80,000,000 aggregate principal amount of convertible notes, consisting of $40,000,000 6% senior convertible notes due in 2027 and $40,000,000 5% senior subordinated convertible notes due in 2012. The 6% senior convertible notes have an initial conversion price equal to the lesser of $12.68 or the 5-day weighted average trading price of the common shares preceding any conversion, subject to adjustments in certain circumstances. The Company will pay interest on the 6% senior convertible notes until maturity on May 2, 2027, subject to earlier repurchase, redemption or conversion. The 5% senior subordinated convertible notes were subject to mandatory conversion into common shares under certain circumstances. In connection with this transaction, the Company issued warrants to purchase an aggregate of 2,250,645 common shares until May 2, 2012, at an initial purchase price of $12.68 per share, subject to adjustments in certain circumstances. During the quarter ended June 30, 2007, $10,500,000 of the 6% senior convertible notes were converted into 1,653,859 common shares and the totality of the 5% senior subordinated convertible notes were converted into 4,444,449 common shares. During the quarter ended September 30, 2007, an additional $25,000,000 6% senior convertible notes were converted into 3,965,462 common shares. Net proceeds from the offering were $74,279,000 and, as of Sep
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2015)... 03, 2015 NuevaCare announced today that ... upcoming area seminars. The first event will take place ... Stroke Conference to be held at The Magnolia of ... May 13 during the Dementia Conference to be held ... seminars offer an excellent opportunity to learn about the ...
(Date:5/3/2015)... 2015 It is not too late to register ... in Memory of Lissa Anne Been in Arnold, Missouri on ... family-friendly event to honor her loving memory. It has benefited the ... Just having turned 37, Lissa suffered a brain aneurysm . ... 24, 2012. This event is designed to serve as a remembrance ...
(Date:5/2/2015)... As one of only 30 Illinois companies to ... Achievement and Recognition Program (SHARP) certification, Essentra Specialty ... Illinois Department of Labor to host this special event. ... by the Occupational Safety and Health Administration’s (“OSHA”) Onsite ... meet or exceed all of the necessary regulations and ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 Vancouver fencing company, ... now provide valuable advice to prospective clients related to their ... looking to install railings around their decks and patios. While ... questions that pop up once the person rolls up their ... of installing a railing in finding a gate that matches ...
(Date:5/2/2015)... 2015 ProText Kinetic 2 is a set ... Cut Pro X. ProText Kinetic 2 features 40 ... Cut Pro X . Easily create interactive text videos ... Studios' ProText Kinetic 2. , Using ProText Kinetic is as ... ProText Kinetic presets in the FCPX timeline. Playback the ...
Breaking Medicine News(10 mins):Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2
... Angeles: About one in three children in California is overweight ... by a health insurance company.// ,There are ... comprises 88 satellite cities. ,The number of ... than the rest of California, and nearly doubles the national ...
... in the developing world would benefit from better preparation ... of the// poor’, a BMA report published on Friday. ... healthcare professionals, including 67 doctors, who had recently worked ... illnesses, malaria and nutrition as the biggest health problems ...
... Medical Center researchers have found a new supplemental therapy that ... potential for chronic pain and health-care costs for millions of ... therapy certainly did the trick for Harriet Velevis, a Dallas ... that made it hard to eat or do her job, ...
... study done by researchers from National Institute of Mental ... of two debilitating //childhood mental disorders, pediatric bipolar disorder ... ,When the brain's electrical signals were measured during mildly ... children with SMD, compared with children who had BD. ...
... to a latest research finding, two thirds of the young population ... on this issue. //This research was conducted by beat, an association ... a total of six hundred people who took part in this ... this issue. People in the age group of 14-25 are at ...
... are cloned will not bear any labels to signify the ... there is no necessary to indicate its source. // ... Government on consumption of food from cloned animals is expected ... evaluate and consider the public’s comments on this issue after ...
Cached Medicine News:Health News:Health Workers Need Better Preparation for Developing World 2Health News:New Supplemental Therapy for Common Jaw Disorder 2Health News:Is Extreme Irritability - a Childhood Bipolar Disorder? 2Health News:Is Extreme Irritability - a Childhood Bipolar Disorder? 3
(Date:5/1/2015)... , May 01, 2015 Research and Markets ... "Asian Dermatology Devices Market by Type, by End User - ... The Asian Dermatology Devices market is estimated to grow at ... China holds a larger share in the Dermatology ... Japan . The Asian Dermatology Devices market holds a ...
(Date:5/1/2015)... At the American Association of Neurological Surgeons (AANS) Annual ... , Elekta will highlight Leksell Gamma Knife® Registry ... enormous amount of data – generated by thousands of ... advance clinical research and further optimize patient care. ... allows practitioners to store, retrieve, and analyze Gamma Knife ...
(Date:5/1/2015)... Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC ) today ... 2015, as well as general business updates. Due to ... be held. Key Highlights , Total ... to $206 million from $119 million for the quarter ... (ibrutinib) net product revenue of $247 million was ...
Breaking Medicine Technology:Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 2Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 3Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 2Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 27Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 28Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 29Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 30Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 31Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 32
... from cutting-edge treatment, CHARLESTON, S.C., April 30 ... Charleston was diagnosed with craniosynostosis, a,condition that leads ... causing problems with normal brain and skull growth., ... Amelia,s skull was,growing in an asymmetrical fashion, a ...
... WILMINGTON, Del., April 30 AstraZeneca (NYSE:,AZN) today ... Application,(sNDA) to the U.S. Food and Drug Administration ... (budesonide/formoterol fumarate dihydrate),Inhalation Aerosol for the treatment of ... currently approved for the long-term,maintenance treatment of asthma ...
Cached Medicine Technology:STARscanner, STARband Cranial Helmets Making a Difference in the Lives of Children 2STARscanner, STARband Cranial Helmets Making a Difference in the Lives of Children 3AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 2AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 3AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 4AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 5
... Maximum Xtra, and Maximum ACT introducers ... and specialty hemostasis introducers in the ... premier hemostasis introducers for use in ... angiography, angioplasty, stenting, atherectomy, temporary pacing, ...
... provide outstanding insertion performance, with ... high kink resistance and minimal ... sheath cannula provides optimal strength ... an extra strong dilator to ...
Bx VELOCITY Coronary Stent with HEPACOAT...
A steerable diagnostic catheter with optimal maneuverability...
Medicine Products: